Home » Vicore Pharma Releases Positive Phase 2 Results for COVID-19 Oral Therapy
Vicore Pharma Releases Positive Phase 2 Results for COVID-19 Oral Therapy
Swedish drugmaker Vicore Pharma has reported positive results from a phase 2 study evaluating its oral therapy for treating respiratory infection in hospitalized COVID-19 patients.
The study enrolled 106 infected patients randomized to receive the investigational drug or placebo, with those taking the oral COVID-19 therapy, C21, shown to have a 40 percent reduced risk of requiring supplemental oxygen following seven days of treatment and a 57 percent reduced risk at eight days.
“Our data clearly show that C21 can restore lung function on top of steroids and normalize gas exchange,” said Vicore CEO Carl-Johan Dalsgaard. “A safe oral medication with such properties can become an important complement to vaccines to combat the pandemic.”
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May